Gelteq Ltd(GELS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 6:45 PM ET (Korea 10/24 07:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.45 | Insider Own | - | Shs Outstand | 9.4M | Perf Week | -3.52% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.6M | Perf Month | -21.76% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.98% | Short Float | 9.27% | Perf Quarter | -34.9% |
| Income | -0.00B | P/S | 41.92 | EPS this Y | - | Inst Trans | 5.98% | Short Ratio | 0.19 | Perf Half Y | -38.48% |
| Sales | 0.00B | P/B | 0.51 | EPS next 5Y | - | ROA | -31.56% | Short Interest | 0.52M | Perf YTD | -46.21% |
| Book/sh | 0.85 | P/C | 461.07 | EPS past 3/5Y | -18.35% - | ROE | -43.32% | 52W High | -78.59% ($2.01) | Perf Year | -69.04% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | 0.08% - | ROIC | -48.23% | 52W Low | 11.19% ($0.39) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | -869.36% | Volatility(W/M) | 4.59% 6.66% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | -4107.16% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | -4350.49% | RSI (14) | 36.14 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.09 | Sales Q/Q | - | SMA20 | -13.12% ($0.49) | Beta | -0.34 | Target Price | - |
| Payout | - | Debt/Eq | 0.36 | Earnings | - | SMA50 | -24.57% ($0.57) | Rel Volume | 0 | Prev Close | $0.43 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -35.8% ($0.67) | Avg Volume(3M) | 2.81M | Price | $0.43 |
| IPO | 2024/10/29 | Option/Short | No/Yes | Trades | 89 | Volume | 13,533 | Change | -1.06% |
🧴 This is an Australia-based pharmaceutical and health functional company that develops an <strong>oral gel delivery platform built on proprietary patents</strong>, turning medicines and nutrients into an easy-to-swallow gel form for patients who have difficulty swallowing pills, including children and the elderly. It is a micro-cap Nasdaq-listed company that holds gel formulation technology applicable across a wide range of categories, including prescription drugs, dietary supplements, pet products, sports nutrition, and cannabis-infused products.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
GELS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,192. Peers typically go for $196.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.0%.
Tap to view numbers
It ranks #75 of 83 in the industry
Based on market cap of $5M.
FAQ
What kind of company is GELS?
GELS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of GELS?
The market cap of GELS is approximately $5M, ranking 5,656 within its sector.
What is the 52-week high and low for GELS?
GELS has recorded a 52-week high of $2.01 and a low of $0.39.
